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We present the results of a phase II trial of carboplatin and etoposide (CE) combination as first-line chemotherapy in patients with
recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) after surgery and radiotherapy. We assess the activity and
the tolerability of this combination. 30 patients with GBM (25) and AA (5) were treated with VP-16 (etoposide) 120mgm
 2 and
CBCDA (carboplatin) 100mgm
 2 for 3 days every 4 weeks. Moreover, we performed a retrospective analysis of topoisomerase IIa
gene status using chromogenic in situ hybridisation. The median age was 54 years (21–73 years); Eastern Cooperative Oncology
Group performance score was 0-1 in 25 patients and 2 in five patients. All patients had been previously treated with surgical resection
(21 radical resections) followed by radiation therapy (40–60Gy). We observed six (20%) complete responses, three (10%) partial
responses and 12 (40%) stable diseases, with a response rate of 30%. The median time to progression was 4 months, while
progression-free survival at 6 months was 33.3%. The median survival time was 10 months. Neutropenia occurred in 9 patients: four
patients had grade 4, two patients grade 3 and three patients grade 2. In the conclusion of this clinical trial, the CE combination has
shown activity in recurrent GBM and AA, with a good toxicity profile. Alterations in the copy number of topoisomerase IIa gene
seem to be a rare event and in our series do not influence response to the CE combination.
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Malignant gliomas are a heterogeneous group of brain cancers. For
all types, surgery and radiotherapy are considered the standard
treatment (Cairncross et al, 1994).
Anaplastic astrocytoma (AA) and glioblastoma multiforme
(GBM) (World Health Organisation (WHO) grade 3 and 4,
respectively) together represent 25–35% of brain tumours and
60% of all gliomas (Russell and Rubinstein, 1989). Despite
progress in surgery and adjuvant therapy, patients with high-
grade gliomas still have a dismal prognosis (Galanis et al, 1998).
Repeat surgery may not be feasible because of tumour infiltration
into eloquent areas of the brain, and additional irradiation has
limited control on further tumour growth and would increase the
risk of neurologic toxicity.
Age, histology, extent of surgery and performance status are
important prognostic variables for malignant gliomas.
Age significantly affects survival and histology, particularly
GBM, which is another important prognostic factor: the median
survival from initial diagnosis is 11 months for GBM as compared
with 27 months for AA. Furthermore, multiple clinical trials have
found performance status, either the Karnofsky performance score
or the Eastern Cooperative Oncology Group (ECOG) scale, to be a
significant prognostic variable (Wong et al, 1999). Recently, the
Glioma Outcomes Project data published by Laws et al (2003)
confirmed that resection (compared with biopsy) is also a strong
prognostic factor for survival. Nonetheless, despite the results of
the Glioma Outcome Project, it is still not clear if the extent of
resection represents an independent prognostic factor or if it is a
dependent variable that may reflect resectability rather than
resection itself.
Systemic chemotherapy is not considered a standard treatment
in high-grade gliomas, but it is usually used in relapsing patients
after failure of locoregional therapy.
Carboplatin is an effective alkylating agent in a variety of solid
tumours. It has effects with a strong dose–response relationship in
malignant glioma cells cultured in vitro and there is substantial
evidence that carboplatin is one of the most potent cytotoxic
agents against human gliomas in vitro (Doz et al, 1991; Wolff et al,
1999). Etoposide is a semisynthetic podophillotoxin that acts
against topoisomerase II with demonstrated activity against
gliomas and other brain tumours (Fulton et al, 1996); furthermore,
carboplatin and etoposide cross the blood–brain barrier (Postmus
et al, 1984; Kiya et al, 1992) and have been detected in
cerebrospinal fluid.
The topoisomerase IIa gene is mapped on chromosome 17 and
encodes a 170kDa nuclear enzyme responsible for a cleavage/
rejoining reaction of double-strand DNA allowing the separation
of intertwined DNA strands. During its catalytic cycle, the
enzyme binds covalently to DNA, creating a transient double-
strand DNA break. Through this DNA break, the enzyme allows
the passage of another DNA double-strand helix. Then, DNA is
rejoined and the enzyme dissociates from DNA (Jensen and
Sehested, 1997).
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lEtoposide does not kill cells by blocking the topoisomerase
catalytic function, rather it poisons this enzyme by increasing the
steady-state concentration of its covalent DNA cleavage complexes:
this action converts topoisomerases into physiological toxins that
introduce high levels of transient protein-associated breaks in the
genome of treated cells (Hande, 1998). There is clear evidence both
in vivo and in vitro of strong synergism between carboplatin and
etoposide (Stein et al, 1999). A recent study showed the activity of
a CBCDA (carboplatin)–VP-16 (etoposide)-based therapy in the
treatment of low-grade gliomas in children (Massimino et al,
2002). The efficacy of CBCDA or cisplatin (CDDP) in combination
with etoposide has been evaluated in various schedules in other
trials in high-grade gliomas with various results (Buckner et al,
1990; Boiardi et al, 1991; Jeremic et al, 1992). The role of
topoisomerase IIa in glioma cancer cells is still unclear. Examina-
tion of tumour samples has shown that the enzyme is expressed at
varying frequency (11–36% of high-grade gliomas, 4% of low-
grade gliomas, 7% of medulloblastomas) and in varying amounts
(about 2, 4, o20% and 40% in grade 1–4 astrocytomas,
respectively). Different groups have tried to correlate the expres-
sion of this nuclear protein to anticancer drug response or to
prognosis with unclear results: both low and high expression is
associated with a favourable prognosis (Dingemans et al, 1999;
MacGrogan et al, 2003). In the past few years, interest in
topoisomerase IIa gene amplification has grown because of
correlation with HER2 gene coamplification and with sensitivity
to anthracyclines in breast cancer. However, the role of
topoisomerase IIa gene amplification in high-grade gliomas has
not, to our knowledge, yet been evaluated. For this reason, we
decided to evaluate retrospectively the prognostic and predictive
role of topoisomerase IIa amplification.
The objective of the present study is to assess the activity and
the toxicity of the treatment based on the CBCDA and VP-16
regimen in patients with recurrent high-grade glioma previously
treated with surgery and radiation therapy. Secondary end points
were time to progression (TTP), progression-free survival (PFS)-6,
PFS-12 and overall survival (OS).
PATIENTS AND METHODS
Patient selection
The eligibility criteria for this study included the following: age
X18 years; histological diagnosis of GBM (GBM) or AA;
unequivocal recurrent tumour after surgery and radiotherapy or
evidence of tumour progression after radiotherapy (a minimal
interval of at least 4 weeks from radiotherapy was mandatory); and
signed, informed consent.
Other eligibility criteria were ECOG performance status p2,
stable corticosteroid dose for at least 2 weeks before study entry,
measurable enhancing tumour X1cm, absolute neutrophil count
X1.5 l0
3mm
 3, platelet count 100 l0
3mm
 3, serum creatinine
level p1.2mgdl
 1 and AST level p1.5 times the upper normal
limit. Other situations rendering patients ineligible were any
chemotherapy for recurrent tumour; a history of malignancy other
than in situ carcinoma of the cervix or nonmelanoma skin cancer;
inability to comply with treatment or follow-up; and pregnancy,
lactation or unwillingness to consider effective contraception.
Treatment plan
For this study, CBCDA plus VP-16 were prescribed as follows:
CBCDA (100mgm
 2) and VP-16 (120mgm
 2) both intravenously
each day for 3 days every 4 weeks for a maximum of 12 cycles.
Carboplatin was administered by 30-min infusion before etoposide
infusion, and then etoposide was sequentially administered by 60-
min infusion. Anticonvulsants and antiemetics were prescribed as
required. Doses in subsequent cycles were reduced or the interval
between cycles lengthened for haematological toxicities. Namely,
the doses were reduced by 25% for absolute nadir neutrophil count
less than 0.5 l0
3mm
 3 or platelet count less than 50 10
3mm
 3;
cycles were delayed until the absolute neutrophil count was at least
1.5 10
3l
 1 and the platelet count at least 100 l0
3l
 1. Treatment
was suspended if bone marrow recovery was unsatisfactory after 1
month or in the presence of extrahaematological toxicity grade
X3.
Patient evaluation
All patients have been evaluated for safety and activity according
to the intention-to-treat analysis. Treatment was discontinued for
progressive disease (PD), in case of unmanageable toxicities, or for
any reason at the patient’s request.
Pretreatment evaluation included a history and physical
examination with documentation of all neurologic symptoms and
signs, complete blood cell count, screening biochemistry, chest X-
ray and either a CT or MR scan with and without contrast
enhancement; all tests were performed within 2 weeks of start of
treatment. Eastern Cooperative Oncology Group performance
status and corticosteroid dose were recorded at baseline. During
treatment, a complete blood cell count was performed weekly.
After each cycle of treatment, patients were examined and
neurologic symptoms and signs documented, performance status
and corticosteroid dose were recorded. Re-evaluation was
performed every three cycles with CT or MR scans with the same
methodology used at baseline. Disease re-evaluation was antici-
pated if clinical conditions indicated disease progression.
Response assessment was based on measurable change in
tumour size taking into consideration corticosteroid requirements
and the neurologic examination. Tumour size was considered the
maximum cross-sectional area of the enhancing mass on CT or
MR, and calculated by multiplying the largest cross-sectional
diameter measured in centimetres by the largest diameter
perpendicular to it. Response was defined as follows: complete
response (CR), disappearance of all enhancing tumour on a TC or
RM scan and neurologically stable or improved, with the patient
with steroid off; partial response (PR), X50% decrease in tumour
size on a TC or RM scan, corticosteroid dose stable or reduced,
neurologically stable or improved; PD, X25% increase in tumour
size or any new area of tumour on any follow-up scan,
corticosteroid dose stable or increased and neurologically stable
or worse; all other situations were considered as SD (Macdonald
et al, 1990). In assessing response, surgical defects, areas of
calcification and nonenhancing abnormalities in these predomi-
nantly enhancing tumours were not measured. The response
assessment was performed by an independent panel of neuro-
radiologists.
Topoisomerase IIa analysis
The copy number of topoisomerase IIa was evaluated retro-
spectively in 27 of 30 tumours by chromogenic in situ hybridisa-
tion (CISH).
All reagents for the assay were obtained from Zymed
Laboratories (South San Francisco, CA, USA) and the manufac-
turer’s suggested method was used. Briefly, 4mm thick, formalin-
fixed, paraffin-embedded sections were baked for 30min at 601C
and then deparaffinised 10min in xylene twice and 5min in
ethanol twice. Air-dried tissue sections were placed in a Coplin jar
containing Tris-EDTA at 451C for 20min, and after a wash in SSC
2  were pretreated with enzyme (30 of pepsin 0.4% of HCl 0.1N,
heat at 451 for 30) and after a wash in SSC 2  were dehydrated.
Denaturation was carried out at 901C, followed by hybridisation
at 371C for 16h using a digoxigenin-labelled Topo IIa probe (Spot-
Lightt Topo IIa probe). After hybridisation, stringency washes
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land a blocking step were performed. Signals were detected using
mouse antidigoxigenin and polymerised horseradish peroxidase-
goat anti-mouse followed by development with diaminobenzidine.
Slides were counterstained with eosin–haematoxylin 1:2 or
methyl green 1%. A case of infiltrating ductal carcinoma, with
amplified Topo IIa gene, was used as a positive control and the
normal cells with two spots were used as internal positive controls.
Topo IIa oncogene was evaluated by two operators using a Nikon
microscope under either a  20 dry or  100 oil objective.
Amplification was defined as greater than 10 discrete copies per
nucleus or as a large gene copy cluster (confluent masses of more
than 10 signals) in more than 50% of the nuclei evaluated (Tanner
et al, 2000): we evaluated at least 400 cells in all cases. Low-level
amplification was defined as six to 10 copies per nucleus in more
than 50% of cells. Unaltered gene copy was defined as one to five
copies per nucleus.
Statistical methods
A single-stage phase II study was conducted to determine the
efficacy of CE combination in the treatment of patients with
recurrent high-grade glioma. The targeted accrual goal of 28
patients provided 85% power to differentiate between a response
rate (RR) of 10 and 30%. Specifically, the hypothesis that was to be
tested was as follows: H0: Pp0.1 vs H1: X0.3, where P is the
proportion of patients who responded (CR and PR) to treatment.
The study opened in October 1996 and closed in February 2000.
For the purposes of statistical analysis and reporting, the following
definitions were used: date of diagnosis was the date of the first
surgery for a glioblastoma or an AA; date of progression was the
date of the first scan documenting X25% increase in tumour size
or any new area of tumour or clinical progression (whichever came
first); time to initial response was the interval between the
inclusion of the patient in the trial and the date of the first scan
documenting a X50% decrease in tumour size; time to progression
was the interval between the chemotherapy start date and the date
of progression. NCI common toxicity criteria were used to score
treatment-related side effects. Overall survival was measured from
the chemotherapy start date until the date of death or last follow-
up examination. Retrospectively, we analysed the amplification of
topoisomerase IIa gene.
Table 1 Pretreatment characteristics of all study patients
Characteristic
Age (years)
Median 60
Range 21–73
Sex
Male 18 (60%)
Female 12 (40%)
ECOG PS
0 21 (70%)
1 4 (13%)
2 5 (17%)
Surgery
Radical 21 (70%)
Partial 9 (30%)
Radiotherapy
Yes 30 (100%)
No 0
Range 40–60Gy
Site
Frontal 11 (37%)
Temporal 4 (13%)
Parietal 3 (10%)
Occipital 2 (7%)
Multilobed 10 (33%)
Prior chemotherapy
Yes 0
No 30 (100%)
ECOG¼Eastern Cooperative Oncology Group.
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Figure 1 Kaplan–Meier curves for OS (A) and TTP (B).
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lThe primary end point was the objective RR. Response rates
were analysed by Fisher’s exact test according to age (o60 or X60
years), resection (gross total resection or partial resection/biopsy),
histological type (AA or GBM), ECOG PS (0-1 or 2) and
topoisomerase IIa status (more than two spots per nucleus or
diploid). The secondary end points were PFS, OS and the safety
and tolerability of treatment. The Kaplan–Meier method was used
in the analysis of PFS and of OS. The log-rank test was performed
to compare OS and time to progression distributions by age,
resection, histology, ECOG PS, response to chemotherapy and
topoisomerase IIa status.
RESULTS
Patient characteristics
In all, 30 patients entered the trial; the first began treatment in
October 1996 and the last in February 2000. Their pretreatment
characteristics, including age, performance status, surgery and
dose of radiotherapy are summarised in Table 1.
All 30 patients were eligible and evaluable: 25 had glioblastoma
and five had AA at the time of surgery. All patients were submitted
to surgery followed by radiotherapy. In total, 21 patients (70%)
had a macroscopically complete resection and nine patients had
partial resection at time of surgery; all patients after surgery were
submitted to radiotherapy (range of dose: 40–60Gy; median:
54Gy) of the contrast-enhancing lesion (plus a 2-cm safety margin
and the area of preoperative edema). The median progression-free
interval since completion of radiotherapy (considering both
glioblastoma and AA patients) was 4.5 months (range: 2–26
months); this interval was 4 months in glioblastoma patients
(range: 2–15) and 7 months in AA patients (range: 3–26). Of note,
all but one patients showed relapse after a time X3 months. At the
time of recurrence none of the patients had any surgical approach.
A total of 25 patients (83.3%, 95% CI 66–93%) had a good ECOG
PS score (0-1); and 26 patients (86.7%, 95% 70–95%) were
younger than 70 years. The median time between radiotherapy end
and chemotherapy was 3 months (range: 40 days–25 months).
Chemotherapy
After surgery and radiotherapy, all patients with a recurrence or
residual disease in progression were treated with a CBCDA
(100mgm
 2) plus VP-16 (120mgm
 2) regimen for 3 days every
4 weeks. All the patients were valuable both for response than
toxicity. A total of 115 chemotherapy courses were administered
with a median number of three cycles/patient (range: 1–18). We
observed 6 (20%, 95% CI 10–37%) CRs, 3 (10%, 95% CI 19–51%)
PRs, 12 (40%, 95% CI 25–58%) SD, with a RR (CRþPR) of 30%
and a disease control (CRþPRþSD) of 70%. Nine patients (30%,
95% CI 17–48%) had PD.
In the GBM patient group, we observed three (12%, 95% CI 4–30%)
CR, three (12%, 95% CI 4–30%) PR and 10 (40%, 95% CI 23–59%)
SD, with a RR (CRþP R )o f2 4 %a n dad i s e a s ec o n t r o lr a t e
(CRþPRþSD) of 64%. Nine patients had PD (36%, 95% CI 20–56%).
Univariate analysis showed that RR was significantly correlated
with age o60 years old (P¼0.025) and AA histology (P¼0.006),
while no correlation was found with radical excision, ECOG PS or
topoisomerase IIa status.
Progression, survival and toxicity
At the time of analysis, 26 (86.7%) patients have progressed and 25
(83.3%) patients have died. The median time to progression for all
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Figure 2 Kaplan–Meier curves for TTP (A) and OS (B) according to RR (P¼0.0011 and 0.005, respectively).
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l30 patients was 4 (CI95% 3–5) months, while PFS at 6 months and
at 12 months was 33.3 and 26.7%, respectively (Figure 1). In the
GBM subgroup, median time to progression was 3 months, while
PFS at 6 months and at 12 months was 20 and 8%, respectively.
The median survival time for the entire group of patients was 10
(95% CI 5–13) months, with 93.3% of patients alive at 6 months,
46.7% at 12 months and 26.7% at 18 months.
The median survival time in the GBM group was 9 months with
92% of patients alive at 6 months, 36% at 12 months and 12% at 18
months.
Survival analysis performed by the Kaplan–Meier method
showed that both TTP and OS were significantly correlated with
histology (P¼0.0004 and 0.0007, respectively) and age (P¼0.014
and 0.0025, respectively), but not with surgical resection grade,
ECOG PS and topoisomerase IIa status.
Patients who had response to CE chemotherapy showed a
significantly longer TTP and survival compared with patients with
stable or PD (P¼0.002 and 0.005, respectively; Figure 2).
Treatment-related haematological toxicity (according to NCI
CTC 2.0) occurred in nine patients with neutropenia: four patients
had grade 4, two patients grade 3 and three patients grade 2
(Table 3). One patient had severe ototoxicity. No patient had
febrile neutropenia or documented infection.
Second-line treatment with temozolomide was given to 11
patients either with disease progression or relapsing after CBCDA-
VP16. In this group of patients, no responses were observed and
only four patients had SD.
Laboratory methods
None of the tumours analysed showed amplification of the
topoisomerase IIa gene. As summarized in Table 2, 21 cases
showed only two spots per nucleus, while in six tumours the probe
revealed more than two spots in only a small percentage of cells
(ranging from 5 to 15%), suggesting the presence of clone with
polisomy of chromosome 17 (Figure 3A and B). For statistical
analysis, we evaluated if the presence of more than two spots can
influence response to CE combination.
Our data indicate that the majority of the cells do not have
alterations in the copy number of topoisomerase IIa gene.
DISCUSSION
Survival expectations for patients with high-grade gliomas at the
time of initial relapse are poor.
Treatment strategies used at the time of tumour recurrence are
mainly palliative and include additional surgery, interstitial
Table 2 Topoisomerase IIa gene status
Patient number Topoisomerase IIa gene status
1 Not done
2 Diploid
3 Diploid
4 Not done
5 More than two spots
6 Diploid
7 Not done
8 Diploid
9 More than two spots
10 Diploid
11 Diploid
12 More than two spots
13 More than two spots
14 Diploid
15 Diploid
16 Diploid
17 Diploid
18 Diploid
19 Diploid
20 Diploid
21 Diploid
22 Diploid
23 Diploid
24 Diploid
25 Diploid
26 Diploid
27 More than two spots
28 Diploid
29 More than two spots
30 Diploid
Figure 3 (A and B) Evidence of more than two dots in the cells as
shown by the arrows.
Table 3 Adverse events reported in patients (n¼30) during CE (115
cycles)
NCI-CTC grade 3 or 4
Adverse event No. of patients %
Thrombocytopenia 0 0
Neutropenia 6 20
Nausea 0 0
Vomiting 0 0
Constipation 0 0
Ototoxicity 1 3.3
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lbrachytherapy or radiosurgery and chemotherapy. Unfortunately,
many patients are not candidates for additional surgery or
radiotherapy. Thus, systemic chemotherapy is often used in these
patients as the single modality of salvage therapy. At the time of
recurrence different chemotherapy regimens have been used in
clinical trials: traditional agents have included nitrosourea drugs
(BCNU-CCNU) and procarbazine. More recently temozolomide has
been used in clinical studies. Few clinical trials have used carboplatin
(CBCDA) and etoposide (VP-16) in the treatment of gliomas
(Buckner et al, 1990; Jeremic et al, 1992; Peterson et al, 1996).
Carboplatin is an alkylating agent widely used in the treatment
of human tumours, and the synergistic effect when used together
with etoposide has been proved either in vitro and in vivo.
Carboplatin has exhibited activity against malignant glioma in
vitro (Dodion et al, 1988), and it has been widely used to treat both
paediatric (Gaynon et al, 1990; Friedman et al, 1992; Gururangan
et al, 2002) and adult (Poisson et al, 1991; Twelves et al, 1991;
Yung et al, 1991; Warnick et al, 1994) brain tumour patients.
In the current clinical trial, the CE combination demonstrated
activity in patients with recurrent high-grade glioma with an
overall RR of 33.3%. The evaluation of activity of this chemother-
apy regimen has to be considered in the light of the selection of
patients: the majority of patients had a low ECOG PS score and
were younger than 70 years, five patients had AA histology (three
of these five patients had CR). These findings may explain a
favourable response to chemotherapy in our study. A recent study
(Braybrooke et al, 2003) showed that cisplatin and etoposide
phosphate (EP) activity is significantly influenced by topoisome-
rase IIa expression levels in patients with advanced breast cancer.
In this experience, we evaluated the topoisomerase IIa gene status
without finding any amplification of the topo IIa gene in our series
of tumours. This genomic alteration does not seem to be involved
in glioma tumorigenesis. We observed in a few cases (22.2%) an
increase in number probably due to polisomy of chromosome 17,
but this numeric alteration of topoisomerase IIa gene copies seems
not to influence disease control rate and survival. These data may
be due to the low incidence of this alteration found in our series.
In this phase II study, the CE regimen showed a favourable
toxicity/activity profile: 10 patients had toxicity and only four of
them had grade 4 toxicity with a relevant RR in patients with high-
grade gliomas. It is worth noting that we did not use the AUC
calculation for the carboplatin individual dosage, and this could be
reflected in some underdosages of the drug. However, this regimen
should be considered as a good therapeutic option for malignant
gliomas and should also be evaluated in more chemosensitive
settings such as recurrent oligodendrogliomas.
New approaches to chemotherapy treatment are necessary;
biological studies to identify novel therapeutic targets will be
useful to find new ways for cancer treatment. The enrolment of
patients into rigorous, well-conducted clinical trials, both at
tumour diagnosis and after recurrence, will generate new
information with regard to investigational therapies, and may
offer improved therapies for patients with malignant gliomas.
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